A Cost–Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care

A Cost–Consequence Analysis of Preemptive <i>SLCO1B1</i> Testing for Statin Myopathy Risk Compared to Usual Care

There is a well-validated association between <i>SLCO1B1</i> (rs4149056) and statin-associated muscle symptoms (SAMS). Preemptive <i>SLCO1B1</i> pharmacogenetic (PGx) testing may diminish the incidence of SAMS by identifying individuals with increased genetic risk before stat...

Full description

Saved in:
Bibliographic Details
Main Authors: Charles A. Brunette, Olivia M. Dong, Jason L. Vassy, Morgan E. Danowski, Nicholas Alexander, Ashley A. Antwi, Kurt D. Christensen
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
<i>SLCO1B1</i>
statin-associated muscle symptoms
pharmacogenetics
cost–consequence analysis
cardiovascular disease
precision medicine
Medicine
R
Online Access:https://doaj.org/article/bce280f5a3324b0bba6cd0a0da6a1f6f
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/bce280f5a3324b0bba6cd0a0da6a1f6f

Similar Items